Tumor angiogenesis is essential for tumor growth and metastasis and is dependent on key angiogenic factors. Angiogenin (ANG), a 14.2-kDa polypeptide member of the RNase A superfamily, is an angiogenic protein that has been reported to be upregulated and associated with poor prognosis in some human cancers. The mechanisms through which aberrant ANG levels promote specific steps in tumor progression are unknown. Here, we show that ANG expression in human tissues is strongly correlated with an invasive cancer phenotype. We also show that ANG induces cellular survival, proliferation, endothelial tube formation and xenograft angiogenesis and growth. Novel mechanistic investigations revealed that ANG expression stimulated matrix metallopeptidase-2 (MMP2) expression through the phosphorylation of ERK1/2. Targeting ANG in vivo with N65828, a small-molecule inhibitor of the ribonucleolytic activity of human ANG, resulted in the diminution of xenograft tumoral growth through the inhibition of angiogenesis. Our findings support an unrecognized interplay between ANG, ERK1/2 and MMP2 that can impact tumor growth and progression. The targeting of ANG and associated factors could provide a novel strategy to inhibit tumor establishment and growth.
INTRODUCTION
The progressive growth of primary neoplasms and metastases is dependent on an adequate blood supply. The process of neovascularization, that is, angiogenesis, is required for tumors to expand beyond 1-2 mm 3 . 1,2 Accordingly, benign tumors are sparsely vascularized and tend to grow slowly, whereas malignant neoplasms are highly vascularized and can grow rapidly. 2, 3 The increase in vasculature also increases the probability that motileinvasive tumor cells may enter the circulation to disseminate to distant organs. 4 The extent of vascularization differs between malignancies, and has been shown to correlate directly with metastatic potential. 5 The induction of angiogenesis is mediated by positive and negative regulatory molecules released by tumorassociated epithelial cells, endothelial cells, mesothelial cells and leukocytes. 2, [6] [7] [8] [9] [10] The balance between these regulating molecules determines the extent of tissue vascularization. 8 The major endogenous inhibitors of angiogenesis include thrombospondin and interferons, 9 while the major endogenous promoters of angiogenesis include vascular endothelial growth factor, 11 interleukin 8 (CXCL8), 12, 13 fibroblast growth factor, 13 and platelet-derived endothelial cell growth factor. 14 Angiogenin (ANG) has been understudied as an angiogenic factor in the development of human cancers. ANG is a 14.2-kDa angiogenic protein originally isolated from conditioned media of HT-29 colon adenocarcinoma cells. 15 Its expression is noted to be upregulated in some cancers [16] [17] [18] [19] [20] and has been linked to worse clinical prognosis in one study. 21 We have previously reported ANG levels to be elevated in voided urines from patients with bladder cancer, and thus may be a viable diagnostic biomarker, 19, 20 but no mechanistic studies have been performed in human bladder cancer models.
ANG production and secretion may be stimulated by hypoxia. 22 ANG is taken up by endothelial cells by receptor-mediated endocytosis and rapidly translocates to the nucleus, a process essential for its angiogenic activity. In the nucleus, ANG cleaves tRNA and promotes ribosomal RNA transcription affecting a wide variety of responses including proliferation, cell migration and invasion and tube formation. 23 All of these are necessary steps for neoangiogenesis in tumors. Nuclear ANG cannot be detected in normal, non-endothelial cells, 23 however, its expression in human cancer cells and human tumors has not been widely investigated. As ANG has important roles in angiogenesis and the growth of many tumors, and as tumors with increased expression of ANG exhibit worse prognosis, we sought to shed light on the mechanism by which ANG influences angiogenesis and supports cancer growth.
RESULTS

ANG expression is upregulated in human cancers
Immunohistochemical (IHC) evaluation revealed that ANG is not expressed in benign bladder tissues (Figure 1a ). Figure 1 shows representative pictures of absent (0; Figure 1b ), weak (1 þ ; Figure 1c ) and strong (3 þ ; Figure 1d ) ANG staining. Figure 1e shows an example of heterogeneous intratumoral ANG expression. Notably, stromal tissue within benign bladder tissues was negative (Figure 1a ), however, stromal tissue associated with bladder tumors did express ANG (Figure 1f ). High-grade, muscle-invasive tumors exhibited the strongest ANG expression ( Figure 1g ). ANG expression was noted to be increased in cancerous bladder tissue compared with benign bladder tissue (P ¼ 0.017; Figure 1h ). Furthermore, the difference in ANG expression in various grades and stages was significant (low-grade vs high-grade, Po0.0001; non-muscle invasive bladder cancer (NMIBC) vs muscle invasive bladder cancer (MIBC), P ¼ 0.001, Figure 1h ), indicating that ANG expression increases with both grade and invasiveness in human bladder tumors. In addition, IHC staining for p-ERK1/2 and MMP2 was performed in benign bladder tissue, low-and high-grade bladder cancer, and NMIBC and MIBC ( Supplementary  Figures 1A-F ). p-ERK1/2 expression and MMP2 expression increased with tumor grade and tumor stage and correlated with ANG expression (Supplementary Figure 1G) .
To test whether this phenomenon was evident in other cancers, we evaluated ANG expression in a tissue microarray (TMA) comprises human cervical cancer specimens. ANG expression was noted to be increased in cancerous cervical tissues compared with benign cervical tissues (P ¼ 0.032); however, no significant increase in ANG expression was noted in high-grade or high-stage cervical cancer (Supplementary Figure 2 ). ANG expression stimulates proliferation, clonal growth and endothelial tube formation Given the progressive upregulation of ANG in human bladder and cervical cancers, we investigated how ANG influences key tumor cell and endothelial cell processes. Evaluation of the human cell lines UROtsa, RT4, T24 and HeLa demonstrated a range of ANG expression levels, with the bladder cancer cell line T24 expressing the highest level of ANG (Figure 2a ). To test the influence of ANG on cell behavior, we created stably transfected ANG-overexpressing UROtsa cells (UROtsa-ANG clones 3 and 7), and transiently transfected T24 and HeLa cells with specific small-interfering RNAs (siRNAs) to knockdown ANG. ANG expression in these cells at the protein ( Figure 2b ) and mRNA levels ( Figure 2c ) was confirmed. In addition, secreted ANG was monitored in the cell-culture media using a commercial ELISA. As expected, secreted ANG correlated with cellular ANG expression levels ( Figure 2d ).
In an in vitro proliferation assay at 72 h, proliferation of manipulated cell lines correlated with ANG expression relative to empty vector controls (Supplementary Figure 3A ) (that is, increased ANG expression increased cellular proliferation potential). Evaluation of anchorage-dependent growth in a soft agar assay showed notable reduction in colony formation efficiency in cells with silenced ANG expression. After 10 days, there was up to X48 and X45% inhibition in colony formation by ANG knockdown in T24 and HeLa cells, respectively. Conversely, UROtsa cells expressing high levels of ANG were noted to have up to a X70% increase in colony formation compared with their control counterparts ( Supplementary Figures 3B and C) . To test whether ANG might influence endothelial cell behavior, we treated human umbilical vein endothelial cell (HUVEC) cultures with conditioned . T24 and HeLa cells were transiently transfected with NC siRNA or siRNA directed at ANG mRNA (ANG si-1 and si-2). Western blot analysis demonstrated altered ANG expression in the two selected UROtsa-ANG clones 3 and 7 and two siRNA-transfected cells for T24 (T24 ANG si-1 and si-2) and HeLa (HeLa ANG si-1 and si-2). b-Actin served as a loading control. (c) Quantitative RT-PCR confirmed ANG overexpression in UROtsa clones and ANG knockdown in the T24 and HeLa transfected cells. (d) ANG ELISA confirmed altered secretion of ANG in line with the above protein and mRNA expression. (e) Capillary tube formation in HUVECs cultured in conditioned media from each of the above manipulated cell lines was quantified as total tube length per field. Tube formation was reduced when ANG expression was silenced. Data from one representative experiment are presented as mean ± s.d., *Po0.05; **Po0.01; ***Po0.001. media from the above manipulated cell lines. In a tube-formation assay, the total length of structures formed by HUVECs on growth factor reduced Matrigel was significantly enhanced (B200%) when treated with media from UROtsa-ANG clones (Figure 2e ). Accordingly, the total length of tube-like structures was significantly reduced when treated with conditioned media from ANG-knockdown T24 and HeLa cells (B26 and B36%, respectively; Figure 2e ).
ANG enhances xenograft growth and angiogenesis
To investigate the influence of ANG in xenograft models, we tested the growth of the UROtsa ANG-expressing clone (ANG clone 7) and T24 and HeLa cells stably transfected with ANG-targeting short hairpin RNA (shRNA) vectors ( Figure 3a) . The three manipulated cell lines (and the corresponding controls transfected with empty vectors) were inoculated subcutaneously into athymic mice. The benign UROtsa cell line is naturally minimally tumorigenic in athymic mice forming a nodular growth that quickly plateaus and arrests within 2-3 weeks ( Figure 3b ). However, the UROtsa-ANG clone 7 cells did form a palpable xenograft tumor that continued to grow significantly beyond the control (P ¼ 0.009) until termination at week 7 post inoculation ( Figure 3b ). Knockdown of ANG in both T24 and HeLa cells correspondingly resulted in a significant reduction in xenograft tumor growth relative to control cells (P ¼ 0.0036 and 0.0003, Figure 3 . Angiogenin increases tumorigenicity in xenograft models. (a) Western blot analysis for ANG confirmed that UROtsa cells with stable expression of ANG (UROtsa ANG clone 7) and T24 and HeLa cells with stable knockdown by shRNA (T24 and HeLa shANG clones, respectively) were available for in vivo studies. shSCR, scrambled control shRNA. (b) UROtsa Empty (Control), UROtsa ANG clone (cl) 7, T24 shSCR (Control), T24 shANG, HeLa shSCR (Control) and HeLa shANG were injected subcutaneously in 6-week-old athymic (nu/nu) mice. Tumor size, recorded over 6 weeks, was plotted as mean±s.d. for the two groups per cell line (n ¼ 10/group). Tumors expressing ANG were noted to have a growth advantage compared with tumors with a reduction in ANG expression. (c) Immunostaining of tumors for ANG and CD31 is shown (original magnification Â 400 and Â 200, respectively). A reduction in CD31 expression was correlated with a reduction in ANG expression. (d) MVD was quantified based on CD31 immunostaining. Data are presented as mean ± s.d., *Po0.05; **Po0.01; ***Po0.001. respectively), confirming that ANG expression correlates with the ability to form tumors in xenograft models ( Figure 3b ). Analysis of excised xenograft tumors revealed a correlation between ANG expression, tumor growth and angiogenesis. Vasculature visualization through CD31 immunostaining (Figures 3c and d ) revealed a 60% increase in microvessel density (MVD) in UROtsa-ANG clone 7 tumors (P ¼ 0.001), while MVD in the T24 shANG xenograft tissues was decreased by 40% (P ¼ 0.0077), and in HeLa shANG xenografts by 40% (P ¼ 0.029). Immunostaining of xenograft tissues also revealed a positive correlation between ANG and the expression of other key angiogenic factors, including vascular endothelial growth factor, interleukin 8, p-ERK1/2 and MMP2 ( Supplementary Figure 4 ).
ANG-associated gene expression patterns
On the basis of our findings that ANG can influence HUVEC tube formation and the angiogenesis index in xenografts, we performed a limited gene expression profiling of our cell line panel to identify changes in associated angiogenic factor expression. A PCR array containing 84 targets was queried and significant fold change deviations were recorded ( Supplementary  Table) . Among the genes that were noted to consistently correlate with ANG expression was MMP2, interleukin 1B and CXCL10. Confirmed by reverse transcriptase (RT)-PCR, the two UROtsa-ANG clones (3 and 7) had increased MMP2 expression, and T24 and HeLa ANG-knockdown cells had decreased MMP2 expression ( Figure 4a ). Interleukin 1B and CXCL10 could not be consistently correlated with ANG expression (data not shown). The coregulation of ANG and MMP2 was confirmed by western blot analysis ( Figure 4b ).
Inhibition of ANG effects by small-molecule inhibitor
The compound 8-amino-5-(4 0 -hydroxybiphenyl-4ylazo)naphthalene-2-sulfonate (N65828) is a known small-molecule inhibitor of ANG activity. 24, 25 Previous reports have shown that both nuclear translocation of ANG and ribonucleolytic activity of ANG are essential for its biological activity. 26, 27 N65828 works by disrupting the ribonucleolytic activity of ANG, which can be measured by its ribonucleolytic activity toward yeast tRNA. 28 By performing an in vitro ANG activity assay, we confirmed that 10 mM of N65828 is able to inhibit ribonucleolytic activity ( Figure 5a ). To test whether N65828 could negate the ANG-dependent changes we had observed in this study, we repeated many of the in vitro assays in the presence of varying doses of N65828. A significant inhibition in cellular proliferation was noted in UROtsa, T24 and HeLa cell lines treated with N65828 at reasonable IC 50 values (3.2±0.8 mM, 1.3±0.5 mM and 1.9±0.4 mM, respectively) ( Figure 5b ). To investigate whether targeting ANG might inhibit tube formation, we treated HUVECs with recombinant human ANG (rhANG) in the presence of increasing doses of N65828. The total length of tube-like structures formed by HUVECs on Matrigel was significantly enhanced with the addition of 100 ng/ml of rhANG compared with control (5.9-fold, P ¼ 0.0005), and the effect was significantly inhibited upon the addition of 0.5 mM (43% reduction, P ¼ 0.008) and to a greater extent with 2.0 mM (58% reduction, P ¼ 0.002) of N65828 ( Figure 5c ). The addition of N65828 to conditioned media from parental UROtsa, T24 and HeLa cells was capable of inhibiting endothelial tube formation (data not shown). Combined with the effects we observed from the expression and knockdown of ANG in multiple cell lines, the inhibitor data confirm that ANG is a pivotal factor in tumor and endothelial cell phenotype.
ANG signaling
To examine whether the observed effects of ANG are mediated through the activation of a specific pathway, a number of analyses were performed on ANG-knockdown HeLa cells. HeLa cells transiently transfected with control siRNA or with two ANGspecific siRNAs were analyzed using a Cancer 10-Pathway Reporter Array. Concomitant with ANG knockdown, reductions in MAPK/ ERK activity (B35% reduction) and MAPK/JNK activity (B60% reduction) were observed (Figure 6a; Supplementary Figure 5A ). The specificity of these results was confirmed, albeit with less reduction in activity by inhibiting ANG activity with 5 mM of N65828 (Figure 6b ; Supplementary Figure 5B ). Then in both T24 and HeLa cells, we confirmed MAPK/ERK and MAPK/JNK involvement by showing that knockdown of ANG with siRNA, or with N65282, resulted in the reduction of phosphorylated ERK1/2 and phosphorylated JNK (Figure 6c ). This led us to speculate that ANG signaling through MAPK/ERK and/or MAPK/JNK may lead to the expression of MMP2. To test this, we used small molecule inhibitors of ERK1/2 (GSK1120212) and JNK (SB60015) in the described assays and observed that perturbing the MAPK/ERK pathway abrogated the ANG-induced expression of MMP2 (Figure 6d ). The inhibition of the MAPK/JNK pathway with SB60015 did not affect the ANG-induced expression of MMP2 (Supplementary Figure 5C ). Thus, we propose that ANG stimulates MMP2 expression through MAPK/ERK. We were able to confirm this inter-relationship in an endothelial tube formation assay. Inclusion of the ERK1/2 inhibitor (GSK1120212) significantly inhibited the formation of tube-like structures at a concentration of 2 nM, and to a greater extent at 10 nM (Figure 6e ). Accordingly, the inhibition of MMP2 with small-molecule inhibitor ARP100 also resulted in a significant inhibition of tube-like structures (Figure 6e ). Studies are underway to further investigate the proposed novel interplay.
Inhibition of xenograft model by N65828
Having shown the effects of N65828 in vitro, we also tested whether the ANG inhibitor could inhibit tumor growth in the more complex situation (that is, a xenograft model). At the end of 6 weeks of an in vivo study, control T24 xenografts reached an average of 313 mm 3 in size. T24 xenografts treated with 4 mg/kg of N65828 reached 217 mm 3 (P ¼ 0.04) and only 202 mm 3 when treated with 8 mg/kg of N65828 (P ¼ 0.002). These results were confirmed with HeLa xenografts. HeLa tumors in mice treated with 4 and 8 mg/kg of N65828 were significantly reduced (P ¼ 0.006 and P ¼ 0.002, respectively) in size compared with control at experimental end point (Figure 7a ). IHC analysis of excised xenograft tumors noted a reduction in ANG in xenografts treated with N65828 ( Figure 7b ). Furthermore, we confirmed a reduction in p-ERK1/2 and MMP2 in both T24 and HeLa tumors from animals treated with 8 mg/kg of N65828 (Figure 7b ). To monitor associated angiogenic index in these xenografts, MVD was evaluated using CD31 immunostaining (Figure 7b ). Analyses revealed a significant reduction in MVD (angiogenesis) in both T24 and HeLa xenografts treated with 4 and 8 mg/kg of N65828. MVD was reduced in T24 by 36% (P ¼ 0.02) and 51% (P ¼ 0.005) in tumors from animals treated with 4 and 8 mg/kg of N65828, respectively. MVD in HeLa xenograft tumors was reduced by 49% (P ¼ 0.0008) and 58% (Po0.0001) treated with 4 and 8 mg/kg of N65828, respectively (Figure 7c ). To monitor associated proliferative capability in these xenografts, proliferation index was evaluated using Ki-67 immunostaining. Similarly to the reduction in MVD, a reduction in proliferation index was evident in both T24 and HeLa xenografts treated with 4 and 8 mg/kg of N65828 ( Supplementary  Figures 6A and B) . These in vivo observations corroborate the in vitro findings and support a role for ANG regulation of tumor growth through an MMP2, MAPK/ERK signaling interaction. 
DISCUSSION
Our study has shown that ANG is overexpressed in human cancer cells compared with human benign cells. Manipulation of ANG expression in a panel of transformed human cell lines showed that ANG levels correlate not only with endothelial tube formation, but also with cellular survival and proliferation, key factors in describing ANG as an oncogene. Mechanistic investigation revealed that ANG acts through ERK1/2 signaling, which in turn, regulates the expression of the tissue-remodeling enzyme MMP2 ( Figure 6 ). Aberrations in the ERK1/2 signaling pathway have been Angiogenin plays a role in tumorigenesis M Miyake et al noted in B30% of all malignancies and are considered to be involved in the initiation of tumorigenesis. 29 Bladder cancer is an excellent model in which to study the downstream effects of ERK1/2 signaling, since factors in this pathway can be overexpressed in up to 80% of patients with bladder tumors and can lead to tumor growth and invasion. 30 In this study, we present clear evidence that ANG expression positively regulates ERK1/2 signaling. Through pharmacologic inhibition of ANG, as well as siRNA/shRNA reduction of ANG, we show that ANG can activate ERK1/2 signaling and that this in turn regulates MMP2 expression (Figures 4 and 6) . We also found that the ANG smallmolecule inhibitor N65828 can blunt the expression of ANG in tumor cells and stroma associated with tumors ( Figure 7) and can inhibit xenograft tumoral growth with a concomitant reduction in the expression of MMP2 and p-ERK1/2 (Figure 7) . In both bladder and cervical tissue arrays, ANG protein expression was strongly increased in cancerous tissue compared with benign tissue with high-grade bladder cancer and high-stage bladder cancer expressing higher levels of ANG compared with low-grade bladder cancer and low-stage bladder cancer (Figure 1 ; Supplementary Figure 2 ). Limited studies have investigated the expression of ANG in human tumors. In a small study analyzing only 24 human tumor specimens, Miyake et al. 21 reported that the mean level of mRNA ANG expression in MIBC was fourfold higher than in NMIBC and fivefold higher than in benign tissues. Moreover, increased tissue levels of ANG have been detected in cancer patients with aggressive disease and poor prognosis. 31 In addition, the mean serum ANG concentration in patients with MIBC (514.6±211.1 ng/ml) was significantly higher than concentration in the serum of NMIBC patients (381.7±169.3 ng/ml) and elevated serum levels of ANG were associated with a significant reduction in overall survival rate. 21 Similarly in a larger study comprises 417 patients (209 with bladder cancer), the mean serum ANG concentration was significantly higher in bladder cancer patients compared with controls (343.2 ng/ml vs 308.0 ng/ml, respectively; Po0.01). 32 It has been suggested that ANG circulates in an inactive form in the serum and that extravasation of ANG into tissues is required to promote angiogenesis.
Inhibition of ANG using monoclonal antibodies or smallmolecule inhibitors may prevent the growth of human xenograft tumors in athymic mice. 25, 33, 34 One specific inhibitor of ANG is N65828. Screening of 18 310 compounds within the National Cancer Institute Diversity Set and ChemBridge DIVERSet based on inhibition of the ribonucleolytic activity of ANG identified N65828 as a lead compound that inhibited the enzymatic activity of ANG over that of other RNAses and prevented human xenograft growth in nude mice. 24 All cell lines examined in the present study demonstrated inhibition of cellular proliferation with the addition of N65828. However, to investigate whether blocking nuclear translocation of ANG may be of therapeutic value against tumors, we examined the inhibitor activity of N65828 against T24 and HeLa xenograft growth in athymic mice. We have shown that N65828 blocks ANG activity ( Figure 5 ), inhibits ANG-induced angiogenesis ( Figure 5 ) and suppresses xenograft growth (Figure 7) . In the process of tumor angiogenesis, cancer cellderived ANG acts on endothelial cells in a paracrine manner to stimulate neovascularization. Scant animal models have been used to examine the role of ANG in tumor growth. Whereas the antitumor activity was obvious, the mechanism by which they prevented or delayed tumor appearance has not been fully understood. On the basis of the long-held assumption that ANG stimulates angiogenesis, these data seemed to support the proposition that the observed antitumor effects were due to the inhibition of ANG-induced tumor angiogenesis.
MMPs are extracellular matrix remodeling proteases that act as critical mediators of the tumor microenvironment. 35 ANG has been shown to stimulate endothelial cells invasion by binding to actin on the cell surface to form complexes that then dissociate from the cell membrane and activate tissue plasminogen activator. 36, 37 Tissue plasminogen activator catalyzes the conversion of plasminogen into plasmin, which in turn can activate MMPs. 38 One MMPs of particular significance in tumor tissue architecture is MMP2. No studies have linked ANG expression to MMP2. Our results expand these preliminary findings and suggest that via the ERK1/2 pathway, ANG regulates MMP2 expression in human tumor cells, specifically urothelial and cervical cells. These results were substantiated in our IHC staining of human bladder TMA, that is, ANG expression correlated with the expression of p-ERK1/2 and MMP2 ( Supplementary Figure 1) . This finding is of importance since MMPs, including MMP2, are known to have an important role in cancer angiogenesis, invasiveness and metastatic potential. [39] [40] [41] Additional studies are planned to further elucidate the precise mechanism associated with ANG increased expression of MMP2.
Here, we provide evidence that the overexpression of ANG in human cancers compared with benign tissues provides evidence of its importance in the development and propagation of human tumors. Furthermore, we demonstrated that ANG effects are propagated through the regulation of the MAPK/ERK pathway. ANG overexpression enhances the growth of xenograft mouse models of cancer and promoted the expression of key angiogenic factors including MMP2, a novel finding, thereby enhancing host angiogenesis and metastatic potential. We provide evidence that blockade of ANG activity by the small-molecule inhibitor N65828 results in decreased rates of tumorigenicity and angiogenesis in vivo. These data confirm that ANG is (1) involved in cellular survival and proliferation, key factors in describing ANG as an oncogene and (2) implicated in tumor progression, underscoring its value as a novel biomarker and drug target for therapeutic intervention.
MATERIALS AND METHODS
IHC staining of TMAs
Commercial TMAs (BL2082, BL1002 and CR803; US Biomax, Inc., Rockville, MD, USA) were examined by IHC staining using standard protocols as show MAPK/ERK and MAPK/JNK pathway components in T24 (NC siRNA, ANG si-1 and ANG si-2) and HeLa (NC siRNA, ANG si-1 and ANG si-2) cells transfected with control siRNA or siRNA directed at ANG, and treated with N65828. Smaller band is ERK1 (42 kDa), while larger band is ERK2 (44 kDa). b-Actin served as a loading control. (d) Serum-starved T24 and HeLa parental cells were subjected to increasing doses of GSK1120212 30 minutes before the addition of rhANG (100 ng/ml). At 6 h after exposure of rhANG, T24 and HeLa cell lysates were collected and subjected to western blot analysis with the indicated antibodies. Data show that despite ANG stimulation, inhibition of ERK phosphorylation resulted in a reduction in MMP2 and p-ERK1/2 expression. b-Actin served as a loading control. (e) Capillary tube formation in HUVECs cultured on growth factor-reduced Matrigel. Endothelial cell cultures were treated with GSK1120212, ARP100 and/or rhANG. Total tube length per well was calculated in micrometers and changes displayed graphically as a percentage of untreated control. Both GSK1120212 and ARP100 significantly abrogated the angiogenic effects of rhANG. Data from one representative experiment are presented as mean ± s.d., *Po0.05; **Po0.01; ***Po0.001. previously described. 42 Antibody and procedure details are available in Supplementary Material.
Cells and reagents
Human bladder cancer cell lines RT4, T24 (ATCC, Manassas, VA, USA), benign human bladder cell line, UROtsa (a generous gift from Dr Donald Sens at the University of North Dakota School of Medicine, Grand Forks, ND, USA) and human cervical cancer cell line, HeLa (ATCC), were available for analysis. Cell lines were maintained in DMEM or RPMI-1640 media as previously described. 43 Primary HUVECs (Cambrex, East Rutherford, NJ, USA) were cultured in EBM-2 basal media supplemented with the EGM-2 MV Kit (Lonza, Walkersville, MD, USA) containing 2% fetal bovine serum. HUVECs of passages 6-8 were used. N65828, an ANG inhibitor, was purchased from YaBen Chemicals Co., Ltd (Hebei, China). GSK1120212, an MAPK/ERK1/2 inhibitor (Selleck Chemicals, Houston, TX, USA), SB60015, an MAPK/JNK inhibitor (Santa Cruz Biotechnology, Santa Cruz, CA, USA), and ARP100, an MMP2 inhibitor (Santa Cruz Biotechnology) were used in the described experiments.
Immunoblotting
Cell lysate and immunoblotting were performed using standard protocols as previously described. 44 Antibody details are available in Supplementary Material.
Transient transfection of siRNA T24 and HeLa cells were transfected for 6 h with synthesized ANG or negative control siRNA (Invitrogen, Life Technologies, Carlsbad, CA, USA) using 6-well plates with 100 pmol of siRNA and 5 ml of lipofectamine 2000 (Life Technologies). ANG siRNA sequences are available in Supplementary Material.
Quantitative RT-PCR RNA was extracted from cells using the RNeasy mini kit (Qiagen, Valencia, CA, USA) as per manufacturer's instructions. Conversion to cDNA was achieved through High Capacity cDNA Reverse Transcription kit (Life Technologies). Quantitative RT-PCR was carried out using the ABI 7300 Real-Time PCR System (Invitrogen, Life Technologies) in a 20-ml reaction volume containing 1 ml of first-strand cDNA, 1 ml of gene-specific TaqMan primer and probe mix. Primer sets can be found in Supplementary Material. Relative fold changes in mRNA levels were calculated after normalization to b-actin using the comparative Ct method. 45 
Stable transfection of cell lines
A plasmid with a sequence-verified human ANG cDNA cloned within pCMV6-Entry vector and plasmid with vector alone (Origene Technologies, Rockville, MD, USA) were transfected into UROtsa cells using Fugene HD transfection reagent (Roche Diagnostics, Indianapolis, IN, USA) to create UROtsa-ANG and UROtsa-Empty. Similarly, ANG shRNA cloned within pGFP-V-RS vector was transfected into T24 and HeLa cells as well as ANG plasmid scramble (Scr) non-effective shRNA construct within pGFP-V-RS vector (Origene) using Fugene HD. Stable transfectants were selected with 1200 mg/ml of G418 (Life Technologies, Inc.) for UROtsa clones and 0.25 mg/ml of puromycin for T24 and HeLa clones for 14 days and subcloned by limiting dilution in 96-well plates. Integration of the transfected gene into chromosome was confirmed by RT-PCR. Stable cell lines were maintained in media containing 500 mg/ml of G418 for UROtsa clones and in media containing 0.25 mg/ml of puromycin for T24 and HeLa clones.
Measurement of secreted ANG by ELISA
Cells were plated onto 6-well plate at a density of 2 Â 10 5 cells/well. After 48 h, the conditioned media was collected and centrifuged to remove any dead or floating cells. Conditioned media was analyzed by ELISA for ANG (ab99970; Abcam, Cambridge, MA, USA) using a FLUOstar OPTIMA microplate reader (BMG Labtech, Cary, NC, USA).
Cell proliferation and soft agar colony formation assay
Cell proliferation was determined by incorporation of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide into UROtsa-Empty, UROtsa-ANG-clones 3 and 7, negative control (NC) siRNA-transfected T24, ANG siRNA-transfected T24, NC siRNA-transfected HeLa, ANG siRNA-transfected HeLa as well as parental UROtsa, T24 and HeLa treated with N65828 as previously described. 44, 46, 47 Exact protocol details are available in Supplementary Material.
Capillary tube formation assays in vitro
The capillary tube formation assay was conducted as described previously. 46 Details listed in Supplementary Material. RT 2 Profiler PCR Arrays for angiogenesis RNA was recovered and converted to cDNA as described above. RT 2 Profiler 'human angiogenesis' PCR arrays (Catalog # PAHS-024ZA; SA Biosciences, Valencia, CA, USA) were analyzed according to the manufacturer's instructions (www.sabiosciences.com/pcrarraydataanalysis.php) by quantitative RT-PCR carried out using the ABI 7300 Real-Time PCR system. The specificity of the SYBR Green assay was confirmed by melting curve analysis. Relative fold changes in mRNA levels were calculated after normalization to housekeeping control gene targets using the comparative Ct method.
ANG activity assay
A reagent mix was prepared using RNAse-free deionizing water as follows: 40 mM HEPES (pH 7.0), 40 mM sodium chloride, 120 units/ml of Yeast tRNA (Sigma-Aldrich, St Louis, MO, USA) and 0.01% bovine serum albumin. Fifty microliters of phosphate-buffered saline containing 0.1% bovine serum albumin and a panel of different concentrations of recombinant human ANG (0, 5.26, 7.9, 11.9, 17.8, 26.7 and 40 mg/ml) was added to 150 ml of reagent mix (total volume 200 ml). For an ANG inhibiting assay, N65828 was added to the mixture at a final concentration of 10 mM and mixed well. After incubation at 37 1C for 2 h, 200 mM of ice-cold 6% perchloric acid (Sigma-Aldrich) was added to each tube and mixed well. The tubes were incubated on ice for 10 min followed by centrifugation at 13 000 r.p.m. for 20 min. One hundred microliters of supernatant from each tube was added to a tube already containing 100 ml of RNAse-free water and mixed well. Absorbance at 260 nm (Abs 260 ) of each sample was read using NanoDrop ND-2000 (Thermo Scientific, Waltham, MA, USA). A linear curve with the amount of rhANG (mg/well) on the X axis and the adjusted Abs 260 (Abs of samples À Abs of blank) on the Y axis was plotted. ANG activity is expressed by the slope of the plot. At least three independent experiments were performed in triplicate.
Signaling pathway activity assays
To determine the signaling pathways involved in ANG expression, a Cancer 10-Pathway Reporter Array (CCL-101A; SA Biosciences) consisting of 10 dual-luciferase reporter assays were conducted according to the manufacturer's instructions. The reporter assay constructs are coated in a 96-well plate. Only HeLa cells were used in this experiment because of their ease of being transfected. To determine the effect of ANG siRNAs, transient cotransfection of siRNA (2 pmol/well) with reporter constructs was performed. Briefly, 0.3 ml of Lipofectamine 2000 transfection reagent diluted in 50 ml Opti-MEM without serum or antibiotics was added to each well for reverse transfection. Next, HeLa cells (20 000 cells/well) were added to each well and mixed gently. After 24 h of incubation at 37 1C, the transfection medium was replaced with growth medium followed by another 24 h of incubation at 37 1C. Then, to determine the effect of ANG inhibitor, the transfection medium was replaced with growth medium containing 2 or 5 mM of N65828. Dual-luciferase reporter activity was determined using a dual-Glo luciferase reporter assay system (Promega, Fitchburg, WI, USA) according to the manufacturer's instructions. Induced transcription factors were reported as firefly luciferase activity normalized to Renilla luciferase activity. After 24 h of incubation, dual-luciferase reporter activity was determined.
In vivo tumorigenicity
Animal care was in compliance with the recommendations of The Guide for Care and Use of Laboratory Animals (National Research Council) and approved by our local IACUC. First, the subcutaneous tumorigenicity assay was performed in athymic BALB/c (nu/nu) mice, 6 to 8 weeks old purchased from Harlan Laboratories (Indianapolis, IN, USA) by inoculating 10 6 UROtsa-Empty, UROtsa-ANG-cl.7, T24-Scr and T24-shANG and HeLa-Scr, HeLa-shANG cells as described previously. 44, 47 At least 10 animals were in each group. Tumor growth was documented weekly. At the termination of the experiment, mice were killed and tumors resected for IHC analysis. Next, the anti-tumor properties of N65828 were tested in vivo using a similar subcutaneous xenograft model by inoculating 10 6 parental T24 and HeLa cells. After 2 weeks, mice were divided randomly into three groups (control, 4 and 8 mg/kg of N65828) and treatment was initiated. N65828 was administered intraperitoneally daily (Mon-Fri) for 4 weeks. Control mice received vehicle alone on the same schedule. At least 10 animals were in each group. Tumor growth was documented weekly. At the termination of the experiment, mice were killed and tumors resected for IHC analysis.
